Business Context and Reporting Period
This Form 8-K Current Report was filed by iBio, Inc. on February 21, 2013. The report discloses a change in the Company's senior management team effective as of the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and compensation arrangements rather than financial performance.
Material Changes
- Appointment of CFO: Scott Kain was appointed Chief Financial Officer effective February 21, 2013.
- Transition of Predecessor: Douglas Beck, the former CFO, transitioned to the role of Senior Adviser.
- Compensation Package: Mr. Kain received an initial annual base salary of $180,000 and a stock option to purchase 100,000 shares of common stock.
- Option Terms: The stock option exercise price is set at the last trading price on the grant date, with vesting occurring in three equal annual installments starting on the first anniversary of his service.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. No specific risks or contingencies are disclosed in this document other than the standard disclosure that Mr. Kain is employed on an at-will basis and that no undisclosed arrangements exist regarding his selection.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 100,000 stock options granted to Scott Kain.
- Confirm the transition timeline for Douglas Beck's role as Senior Adviser.
- Review the Company's 2008 Equity Incentive Plan to understand the terms governing the new grant.
- Check subsequent filings for any financial impact related to the new executive compensation structure.